Stanford Study Needs Volunteers With Peripheral Artery Disease to Test Dietary Supplement's Effect on Debilitating Leg Pain
Posted on: Tuesday, 25 January 2005, 15:00 CST
When atherosclerosis attacks the legs--hardening and thickening the arteries--it leaves the patient in severe pain. As less blood gets through the vessels, cramping and weakness occurs in the thigh and calf when the person walks or stands. Eventually the pain grows so great that even sitting or lying down offers no relief.
For more than 20 years, John Cooke, MD, PhD, professor of medicine (cardiovascular) at the Stanford University School of Medicine, has specialized in studying this condition, known as peripheral arterial disease, or PAD.
Cooke has focused on developing a simple treatment for the pain. In his work, he has scrutinized the molecules that regulate blood flow, and he has zeroed in on one particular compound that could offer a solution: arginine, an amino acid, one of the building blocks of a protein that is found in dairy, meat, poultry and fish, among other foods.
Cooke is looking for volunteers to participate in a study to determine whether arginine supplements can make people with PAD feel better and allow them to increase the distance they can walk.
"Right now we really don't have an optimal treatment for peripheral artery disease, which affects up to 12 million people," said Cooke, who directs the school's Program in Vascular Medicine and Biology. Although there are two drugs on the market for the treatment of the condition, he added, neither works as well as he would like for his patients.
Such measures as quitting smoking, eating a low-fat, low-salt diet and exercising can halt or even reverse the narrowing of the arteries. But Cooke noted that sometimes a patient is in so much pain that exercising isn't a realistic option.
"Arginine could be a cheap, simple and safe way for people with peripheral arterial disease to increase their walking distance," said Cooke, who started a company called Cooke Pharma in 1997 to make nutritional bars enriched with arginine. (The product was acquired in 2000 by United Therapeutics Corp., which develops a line of arginine-enriched products.)
The National Institutes of Health has funded his latest arginine study, in which Cooke and his colleagues want to examine more than 100 patients at Stanford who suffer from debilitating leg pain and have been diagnosed as having PAD. They will test whether arginine can improve circulation and restore blood vessel function.
As part of the study, some participants will receive arginine supplements, as it's not possible to get adequate amounts of arginine from eating regular food, even in larger quantities. A firm in Japan produces the supplements.
Cooke is one of a number of scientists nationwide studying arginine. Another researcher, Amir Lerman, MD, professor of medicine at the Mayo Clinic College of Medicine, has been leading a group that has been using arginine to improve cardiac blood flow at amounts up to 9 grams per day--or 18 500-mg capsules--with no ill effects. The Stanford study uses lower amounts than this. "There is a scientific basis to (Cooke's) study," Lerman said. "It is based on previous studies and on a scientific mechanism."
The participants in the Stanford study will be randomly divided to take either an arginine supplement or a placebo for six months. Neither the patients nor the researchers will know who is taking the active supplement.
Patients will undergo a full medical exam, blood tests to look for molecules that can indicate risk for cardiovascular diseases, a treadmill test to determine walking ability and visualization of the vasculature by magnetic resonance imaging and ultrasound.
Those interested in participating the study or in obtaining additional information should call (650) 723-4064.
Stanford University Medical Center integrates research, medical education and patient care at its three institutions -- Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.
Source: Business Wire
Related Articles
- Study Lays Foundation For More Patient Access To Medical Records
- LABS Inc. to Offer Donor Testing Services for Transfusion Medicine and Blood Services Industry
- Aeolus Pharmaceuticals Announces Initiation of Multiple Dose Study of AEOL 10150 in a Patient With ALS
- A Major Study Compares Direct Blood Volume Measurement Using the BVA-100 With the BNP Test for Managing Fluid Therapy in the Intensive Care Unit
- ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients
- Companion Technologies Adds Web Interface for Medical Patient Statements
- Clofarabine European Study Confirms Efficacy in Pediatric Patients With Acute Lymphoblastic Leukemia; Study Update at American Society of Hematology
- Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients*
- Experts Say Integration of Chinese, Western Medicine to Prolong AIDS Patients' Lives
- Dalteparin Reduced Venous Thromboembolic Events Without Increased Bleeding in Acutely Ill Medical Patients/COMMENTARY
User Comments (0)

RSS Feeds